Although CRISPR-mediated genome editing holds promise for cancer therapy, inadequate
tumor targeting and potential off-target side effects hamper its outcomes. In this study, we …

Since its mechanism discovery in 2012 and the first application for mammalian genome
editing in 2013, CRISPR-Cas9 has revolutionized the genome engineering field and created …

Lung cancer is the most common cancer worldwide and the leading cause of cancer-related
deaths in both men and women. Despite the development of novel therapeutic interventions …

Harnessing CRISPR-Cas9 technology for cancer therapeutics has been hampered by low
editing efficiency in tumors and potential toxicity of existing delivery systems. Here, we …

Clustered regularly interspaced short palindromic repeats/associated protein 9
(CRISPR/Cas9) gene‐editing technology shows promise for manipulating single or multiple …

While substantial progress has been made in the treatment of lung cancer with the
development of tyrosine kinase inhibitors (TKI s) that target tumor‐driving mutations in the …

Cancer is the second leading cause of death globally and remains a major economic and
social burden. Although our understanding of cancer at the molecular level continues to …

CRISPR-Cas9 has emerged as a powerful technology that relies on Cas9/sgRNA
ribonucleoprotein complexes (RNPs) to target and edit DNA. However, many therapeutic …

In a study recently published in Nature Medicine, Lu et al. examined the feasibility and safety
of using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-engineered …

Clustered regularly interspaced short palindromic repeats (CRISPR) system provides
adaptive immunity against plasmids and phages in prokaryotes. This system inspires the …